Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Veloxis Pharmaceuticals receives European Marketing Authorization for Envarsus


Monday, 28 Jul 2014 02:30am EDT 

Veloxis Pharmaceuticals A/S:Says Envarsus receives European Marketing Authorization for treatment of both kidney and liver transplant patients.Says NDA for Envarsus XR is under regulatory review by FDA and has a PDUFA action date of Oct. 30, 2014.Says does not expect to receive the additional liver indication in the U.S.